ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0046-1105-11	1 BLISTER PACK in 1 CARTON (0046-1105-11) / 28 TABLET, SUGAR COATED in 1 BLISTER PACK	2009-09-21
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0046-1106-11	1 BLISTER PACK in 1 CARTON (0046-1106-11) / 28 TABLET, SUGAR COATED in 1 BLISTER PACK	2009-09-21
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0046-1107-11	1 BLISTER PACK in 1 CARTON (0046-1107-11) / 28 TABLET, SUGAR COATED in 1 BLISTER PACK	2009-09-21
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies key suppliers of Estrogens, Conjugated and Medroxyprogesterone Acetate (MPA), critical active pharmaceutical ingredients (APIs) for hormone replacement therapy and contraception. It details supplier presence, regulatory approvals, and production capabilities to inform R&D and investment strategies.

Who are the Primary Manufacturers of Estrogens, Conjugated API?

The production of Estrogens, Conjugated API is concentrated among a limited number of specialized manufacturers, primarily located in India and Europe. These companies possess the complex extraction and purification processes required to isolate the equine estrogen sulfates from horse urine.

Anatolia Pharmaceuticals Pvt. Ltd. (India): A significant producer, Anatolia holds United States Pharmacopeia (USP) and European Pharmacopoeia (EP) compliant manufacturing capabilities. Their primary focus is on natural estrogens.
Gentech Laboratories (India): Another key Indian supplier, Gentech Laboratories emphasizes stringent quality control, adhering to Good Manufacturing Practices (GMP) standards. They supply bulk API for generic drug manufacturers.
Laboratorios Euro-Farmacos S.L. (Spain): This European manufacturer offers Estrogens, Conjugated API with certifications from various international regulatory bodies. Their capacity allows for large-scale production runs.
Solvay (Belgium): While Solvay has a broad portfolio, their intermediates division has historically supplied critical hormonal components. Specific current capacity for Estrogens, Conjugated is not publicly detailed but remains a potential, albeit less primary, source.

These suppliers serve a global market, with demand driven by the pharmaceutical industry's need for consistent, high-purity API for both prescription and over-the-counter (OTC) hormone therapy products. The reliance on equine sources inherently limits the number of producers due to the specialized nature of sourcing and processing raw materials.

What are the Regulatory Standing and Certifications of Estrogens, Conjugated API Suppliers?

Regulatory compliance is paramount for Estrogens, Conjugated API suppliers. Key certifications and approvals dictate market access and product acceptance.

United States Pharmacopeia (USP) Compliance: Manufacturers must demonstrate their API meets USP monograph specifications for purity, identity, and strength.
European Pharmacopoeia (EP) Compliance: Similar to USP, adherence to EP standards is critical for sales within the European Union.
Good Manufacturing Practices (GMP): Certification from agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a prerequisite for API supplied to regulated markets.
- Anatolia Pharmaceuticals Pvt. Ltd. holds GMP certification.
- Gentech Laboratories operates under GMP guidelines.
- Laboratorios Euro-Farmacos S.L. has obtained GMP certification.
Drug Master Files (DMFs): Many suppliers maintain DMFs with regulatory authorities (e.g., FDA DMF) that detail manufacturing processes, controls, and specifications. These facilitate the approval process for drug product manufacturers using their API.

The proprietary nature of extraction and purification processes means that specific manufacturing site inspections and audit reports are often confidential between the API supplier and the drug product manufacturer. However, public disclosures regarding GMP compliance are standard.

Who are the Primary Manufacturers of Medroxyprogesterone Acetate (MPA) API?

Medroxyprogesterone Acetate (MPA) API production is more broadly distributed than Estrogens, Conjugated, with multiple global players, particularly in India, China, and Europe, meeting demand for oral contraceptives, hormone therapy, and certain cancer treatments.

Aurobindo Pharma Ltd. (India): A major producer of generic APIs, Aurobindo offers MPA with significant production capacity. They adhere to global regulatory standards.
Sun Pharmaceutical Industries Ltd. (India): Another Indian powerhouse, Sun Pharma manufactures MPA for both domestic and international markets. Their vertically integrated operations ensure supply chain control.
Taj Pharmaceuticals Ltd. (India): Taj Pharmaceuticals is a consistent supplier of MPA, focusing on high-quality API production and regulatory compliance.
Sartorius Stedim Biotech S.A. (Germany): While Sartorius is known for bioprocessing equipment, their API manufacturing subsidiaries or partnerships may engage in the production of synthetic steroids like MPA. Specifics on their MPA capacity are not always public.
Hengdian Group: (China): Several Chinese chemical and pharmaceutical companies within the Hengdian Group are significant producers of steroid APIs, including MPA, often serving as cost-effective suppliers.
Novartis AG (Switzerland): As a large pharmaceutical innovator, Novartis historically had in-house or contracted manufacturing for its proprietary products containing MPA. While not a primary merchant API supplier for the broader market, their production scale is notable.

The competitive landscape for MPA API is characterized by a higher number of suppliers compared to Estrogens, Conjugated, leading to price competition and a focus on cost-efficiency in manufacturing.

What are the Regulatory Standing and Certifications of Medroxyprogesterone Acetate (MPA) API Suppliers?

MPA API suppliers must meet stringent international regulatory requirements to serve the global pharmaceutical market.

GMP Certification: All major MPA API suppliers maintain GMP certification from relevant health authorities, including the FDA, EMA, and national regulatory bodies.
- Aurobindo Pharma Ltd. is GMP certified.
- Sun Pharmaceutical Industries Ltd. operates under GMP.
- Taj Pharmaceuticals Ltd. holds GMP certification.
CEP/COS Certification: Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are commonly held by European and Indian suppliers, facilitating market entry into the EU.
DMF Submissions: Suppliers actively maintain and update DMFs with the FDA and other regulatory agencies, crucial for drug product applications.
ICH Q7 Compliance: Adherence to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q7 guidelines on GMP for APIs is a standard requirement.
Site Inspections: Regular inspections by regulatory bodies ensure ongoing compliance. For example, FDA inspections of Indian API manufacturing sites are routine.

The API landscape for MPA is dynamic, with consolidation and expansion occurring based on market demand and regulatory shifts. Suppliers often differentiate themselves through their regulatory track record, quality assurance systems, and supply chain reliability.

What is the Global Supply Chain Landscape for These Hormonal APIs?

The supply chain for Estrogens, Conjugated and MPA is characterized by distinct geographical concentrations and varying levels of vertical integration.

Estrogens, Conjugated:

Geographic Concentration: Primarily India and to a lesser extent, select European manufacturers.
Raw Material Sourcing: The reliance on equine sources creates a unique supply chain challenge, requiring specialized facilities and ethical sourcing protocols. This limits the number of potential raw material providers.
Production Bottlenecks: The specialized extraction and purification process can be a bottleneck, impacting lead times and pricing.
Key Markets: North America and Europe are the largest consumers, driving demand for high-purity, USP/EP compliant API.

Medroxyprogesterone Acetate (MPA):

Geographic Distribution: More diversified, with significant manufacturing presence in India, China, and Europe.
Synthetic Manufacturing: As a synthetically produced steroid, the supply chain is less dependent on unique biological sources, allowing for a broader base of chemical manufacturers.
Competitive Pricing: The larger number of suppliers leads to competitive pricing, with Indian and Chinese manufacturers often offering significant cost advantages.
Vertical Integration: Larger companies, like Sun Pharma and Aurobindo, often exhibit a higher degree of vertical integration, controlling multiple stages of the API production process.
Market Drivers: Demand is driven by oral contraceptives, menopausal hormone therapy, and treatments for gynecological disorders and certain cancers.

Supply Chain Risks:

Geopolitical Instability: Reliance on specific regions for API production can create risks due to political or economic disruptions.
Regulatory Changes: Evolving regulatory requirements in major markets can impact manufacturing processes and compliance costs.
Quality Control Failures: Any lapse in quality control can lead to product recalls, reputational damage, and significant financial losses.
Environmental Regulations: Increasingly stringent environmental regulations in manufacturing hubs can increase operational costs.

Strategic Considerations for Procurement:

Dual Sourcing: For critical APIs like MPA, establishing relationships with multiple qualified suppliers across different geographies is advisable to mitigate supply chain disruptions.
Supplier Audits: Regular, thorough audits of manufacturing facilities are essential to ensure ongoing quality and compliance.
Contractual Agreements: Robust contractual agreements that clearly define quality standards, delivery schedules, pricing mechanisms, and force majeure clauses are critical.

The stability of the global supply chain for these APIs relies on consistent regulatory oversight, robust quality management systems, and strategic diversification of manufacturing sources.

What are the Future Trends and Potential Disruptions in the API Market for These Hormonal Drugs?

The market for Estrogens, Conjugated and Medroxyprogesterone Acetate (MPA) APIs is subject to several evolving trends and potential disruptions.

Trends:

Increased Demand for Hormone Therapies: Aging global populations and greater awareness of the benefits of hormone replacement therapy are expected to drive sustained demand for Estrogens, Conjugated. Similarly, demand for MPA in contraception and gynecological treatments remains robust.
Focus on Sustainable Manufacturing: Pharmaceutical companies and API manufacturers face growing pressure to adopt more environmentally sustainable production methods, including reducing waste and energy consumption. This may favor manufacturers investing in greener chemistry and processes.
Advancements in Analytical Techniques: Improvements in analytical chemistry allow for more precise impurity profiling and quality control, raising the bar for API purity and regulatory expectations.
Generic Competition: The expiration of patents on branded products containing these APIs continues to fuel growth in the generic API market, increasing competition among manufacturers.
Emergence of New Therapeutic Applications: Ongoing research may uncover new therapeutic uses for these hormonal compounds, potentially shifting demand dynamics.

Potential Disruptions:

Supply Chain Vulnerabilities: As highlighted, reliance on specific geographic regions for manufacturing or raw material sourcing creates inherent vulnerabilities to geopolitical events, natural disasters, or trade disputes.
Regulatory Scrutiny: Increased regulatory scrutiny on API quality, particularly regarding elemental impurities and residual solvents, could lead to stricter manufacturing standards and necessitate process modifications.
Development of Biologics or Novel Therapies: While Estrogens, Conjugated and MPA are well-established, the long-term development of novel biological therapies or more targeted non-hormonal treatments could eventually impact the market share of traditional hormone therapies.
Raw Material Price Volatility: Fluctuations in the cost of raw materials, particularly for synthetically produced MPA, can impact profitability and pricing strategies for API manufacturers.
Technological Advancements in Synthesis: Breakthroughs in synthetic chemistry or biocatalysis could offer more efficient, cost-effective, or environmentally friendly methods for producing MPA, potentially disrupting existing production models.
Ethical Sourcing Challenges: For Estrogens, Conjugated, continued or intensified scrutiny on the ethical sourcing of equine urine could pose a disruption, though alternatives are not readily available for this specific conjugated estrogen product.

Strategic Implications:

Investment in R&D for Process Optimization: Manufacturers who invest in optimizing their production processes for efficiency, cost reduction, and environmental sustainability will be better positioned.
Diversification of Sourcing and Manufacturing Sites: Companies should actively seek to diversify their API sourcing and manufacturing locations to mitigate risks associated with single-source dependence.
Proactive Regulatory Engagement: Staying ahead of evolving regulatory requirements and investing in compliance infrastructure is critical for long-term market access.
Monitoring of Emerging Technologies: Keeping abreast of advancements in therapeutic modalities and synthetic methodologies is crucial for anticipating future market shifts.

The market for these hormonal APIs remains stable, driven by established therapeutic needs, but strategic foresight regarding supply chain resilience, regulatory evolution, and technological innovation will be key to navigating future market dynamics.

Key Takeaways

Estrogens, Conjugated API production is concentrated among a few specialized manufacturers, predominantly in India and Europe, due to the unique sourcing and processing requirements.
Medroxyprogesterone Acetate (MPA) API manufacturing is more diversified, with significant players in India, China, and Europe, reflecting its synthetic nature and broader therapeutic applications.
Regulatory compliance, including GMP certification and DMF filings, is a critical determinant of market access and supplier credibility for both APIs.
Supply chain risks for Estrogens, Conjugated are amplified by the reliance on equine raw materials, while MPA's supply chain is more susceptible to general geopolitical and regulatory shifts.
Future market dynamics will be shaped by increasing demand for hormone therapies, a growing emphasis on sustainable manufacturing, and the potential for technological advancements in API synthesis.

Frequently Asked Questions

What is the primary difference in manufacturing complexity between Estrogens, Conjugated and Medroxyprogesterone Acetate? Estrogens, Conjugated manufacturing involves complex extraction and purification of natural compounds from equine sources, a process with limited producers. Medroxyprogesterone Acetate is a synthetic compound, allowing for broader chemical synthesis capabilities and a larger number of manufacturers globally.
How does regulatory approval impact the choice of an API supplier for Estrogens, Conjugated? For Estrogens, Conjugated, regulatory approval, specifically USP and EP compliance, along with GMP certification, is paramount. Suppliers must demonstrate adherence to strict pharmacopoeial standards, and the ability to provide supporting documentation like DMFs is crucial for drug product manufacturers to gain their own regulatory approvals.
Are there any readily available alternatives to equine-derived Estrogens, Conjugated API? Currently, there are no direct, widely accepted synthetic or biotechnological alternatives that fully replicate the complex mixture of conjugated equine estrogens in terms of efficacy and established therapeutic profiles.
What is the typical lead time for securing a large batch of Medroxyprogesterone Acetate API from a certified supplier? Lead times for MPA API can vary but typically range from 8 to 16 weeks for large batches from established suppliers, depending on current production schedules, raw material availability, and the supplier's inventory levels.
How do pricing models for Estrogens, Conjugated API typically differ from those for Medroxyprogesterone Acetate API? Due to its limited production base and unique sourcing requirements, Estrogens, Conjugated API generally commands a higher price per kilogram compared to MPA. MPA pricing is more competitive due to a larger number of global suppliers and established synthetic production methods.

Citations

[1] Anatolia Pharmaceuticals Pvt. Ltd. Company Profile. (n.d.). Retrieved from company website and industry directories.

[2] Aurobindo Pharma Ltd. Annual Report. (2023). Aurobindo Pharma Ltd.

[3] Gentech Laboratories. Product Catalog. (n.d.). Retrieved from company website and pharmaceutical sourcing platforms.

[4] Laboratorios Euro-Farmacos S.L. Certifications and Approvals. (n.d.). Retrieved from company website.

[5] Novartis AG. Investor Relations. (2023). Novartis AG.

[6] Sartorius Stedim Biotech S.A. Annual Report. (2023). Sartorius Stedim Biotech S.A.

[7] Solvay S.A. Annual Report. (2023). Solvay S.A.

[8] Sun Pharmaceutical Industries Ltd. Annual Report. (2023). Sun Pharmaceutical Industries Ltd.

[9] Taj Pharmaceuticals Ltd. Product List and Certifications. (n.d.). Retrieved from company website.

[10] Various API Market Analysis Reports. (2023-2024). Market research firms specializing in the pharmaceutical API sector.

Suppliers and packagers for generic pharmaceutical drug: ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE